Damara Ortiz, Rare Disease Day 2022: The impact of Pompe disease and the importance of newborn screening
Prof. Damara Ortiz (UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA) joins us for Rare Disease Day to discuss the daily impact that Pompe disease has on patients. Prof. Ortiz discusses how emerging therapies have improved outcomes for children, and how a newborn screening program has been put in place in Pennsylvania to diagnose Pompe disease early and save children’s lives.
Touch Medical Media is supporting Rare Disease Day (28 February 2022) to shine a light on healthcare inequalities for people living with rare diseases, focusing on patient quality of life and the difficulty of diagnosing patients early.
- Could you tell us a little about the spectrum of Pompe disease and the impact on daily life for people living with Pompe disease? (026)
- You’re involved in the newborn screening program for Pompe disease – why is this important for people with the disease? (2:15)
- With new therapies prolonging survival, what more is needed to support people living with Pompe to realise their life goals? (6:22)
Disclosures: Damara Ortiz has received research and grant support from Sanofi-Genzyme and Amicus.
Support: The production of this video was supported by Touch Medical Media.
Other content available in support of Rare Disease Day includes:
Share this Video
Related Videos In Heart Failure
John Boehmer, ACC 2023: The MicrocorTM device for heart failure management, the BMAD trial
Rates of readmission following heart failure hospitalization are high. The BMAD trial in patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Barry Borlaug, ACC 2023: Dapagliflozin in heart failure, an invasive hemodynamic randomized trial
Heart failure with preserved ejection fraction (HFpEF) is a hemodynamic disorder characterized by an elevation of left ventricular filling pressures. This trial assessed the ability of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), to reduce this elevation. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!